HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nutrition & Obesity Medicine
Sys. Review
Tirzepatide maximum tolerated dose leads weight reduction ranking in obesity network meta-analysis
New analysis shows weight loss drugs work best for adults with obesity without diabetes
This systematic review and network meta-analysis of 14,059 adults with obesity without diabetes ranked GLP-1 receptor agonists and a dual ag…
A large review of many studies found that specific injectable medicines help adults lose weight. Tirzepatide worked best, but all options re…
Jun 4, 2026
Psychiatry
RCT
Semaglutide Improves Metabolic Health in Schizophrenia Patients on Antipsychotics
Semaglutide improves blood sugar and weight in people with schizophrenia and prediabetes
A randomized, placebo-controlled trial in 154 overweight or obese individuals with schizophrenia and prediabetes receiving second-generation…
A new trial shows semaglutide helps lower blood sugar and reduce weight in people with schizophrenia who also have prediabetes or obesity.
Diab Care
Jun 4, 2026
Drug Pipeline
Meta-analysis
GLP-1 receptor agonists show no increased ocular disorder risk in type 2 diabetes meta-analysis
New analysis shows GLP-1 drugs do not raise eye disease risk for diabetes patients
This systematic review and meta-analysis of 28 observational studies found that GLP-1 receptor agonists did not increase the risk of NAION, …
A large review of 28 studies found that diabetes drugs called GLP-1 receptor agonists do not increase the risk of eye problems like glaucoma…
Frontiers
Jun 2, 2026
Drug Pipeline
Phase III
Semaglutide 1.7 mg shows comparable BMI reduction to 2.4 mg in adolescents and adults
Lower-dose semaglutide works as well as higher doses for teen and adult obesity
This model-informed analysis combined Phase 3 adolescent and adult semaglutide trial data. Semaglutide 1.7 mg produced a mean BMI change com…
A new analysis shows that a lower dose of semaglutide works just as well as the higher dose for weight loss in teens and adults, with simila…
Jun 1, 2026
Nutrition & Obesity Medicine
Meta-analysis
Cagrisema produces greater weight loss than semaglutide in obesity meta-analysis
New analysis shows cagrisema beats semaglutide for weight loss in obesity
This systematic review and meta-analysis of 3,545 individuals with obesity found that cagrisema produced significantly greater weight loss t…
A large meta-analysis found cagrisema produced greater weight loss than semaglutide, while cagrilintide alone matched semaglutide results in…
Jun 1, 2026
Neurology
RCT
Oral Semaglutide Failed to Slow Clinical Progression in Early Alzheimer's Disease Across Global Phase 3 Trials
Oral semaglutide did not slow Alzheimer's disease progression in early trials
In large phase 3 trials, oral semaglutide showed no benefit over placebo for patients with early Alzheimer's disease. The drug did not impro…
A large trial found that taking oral semaglutide offered no benefit over placebo for people with early Alzheimer's disease.
May 30, 2026
Diabetes & Endocrinology
Meta-analysis
CagriSema demonstrates superior weight loss efficacy compared to semaglutide monotherapy or placebo in obesity trials
New drug combo beats standard treatment for obesity and heart risks
A systematic review and meta-analysis of 4,419 patients reveals CagriSema drives greater weight loss than semaglutide alone. However, clinic…
This new drug combination helps people lose more weight and lowers blood pressure, but it causes more stomach upset that needs careful watch…
May 15, 2026
Diabetes & Endocrinology
Meta-analysis
Bayesian network meta-analysis compares tirzepatide, liraglutide, and semaglutide for weight reduction in adults without diabetes
New Weight Loss Drug Beats Popular Options in Head-to-Head Comparison
This Bayesian network meta-analysis synthesized evidence from 42 randomized controlled trials, six of which were included in the network, to…
A newer weight loss drug helped people drop nearly 14 percent of their body weight, beating two popular options in a major comparison.
May 8, 2026
Diabetes & Endocrinology
Meta-analysis
Network Meta-Analysis Finds Tirzepatide and Sleeve Gastrectomy Equally Effective for Weight Loss in Obesity
New Weight Loss Pill Matches Surgery Results Without the Scalpel
A network meta-analysis of 14,293 adults with obesity found that tirzepatide 10 or 15 mg and sleeve gastrectomy achieved similar weight loss…
A diabetes drug now pulls even with stomach surgery for weight loss offering hope to millions who dread going under the knife but it is not …
May 4, 2026
Nutrition & Obesity Medicine
Meta-analysis
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
Women Lose More Weight on GLP-1 Drugs Than Men Do
This systematic review and meta-analysis examined weight changes among adults with obesity, diabetes, or cardiovascular disease treated with…
• Women lose 11% weight versus 7% for men on these drugs • Helps adults using Wegovy Ozempic and similar weight loss medications • Works sam…
May 4, 2026
Psychiatry
Meta-analysis
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
May 1, 2026
Nutrition & Obesity Medicine
RCT
Semaglutide reduces insulin dose in adults with type 1 diabetes and obesity
Semaglutide Cuts Insulin Needs By Half In Type 1 Diabetes
A post hoc analysis of an RCT found that semaglutide 1 mg/week significantly reduced total daily insulin dose by 22.6% over 26 weeks in adul…
Semaglutide reduces insulin needs quickly in type 1 diabetes patients, offering a new hope for better blood sugar control and weight managem…
Diab Care
May 1, 2026